Theme: Drugs Affecting the Rhythm of Heart

Cardiac Pharmacology 2017
Past Report of Cardiology Summit 2016

Cardiac Pharmacology 2017

Conference series LLC Conferences invites all the participants from all over the world to attend “6th Global Experts Meeting on Cardiovascular Pharmacology and Cardiac Medications” during April 13-14, 2017 in Dubai, UAE. This includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Cardiac Pharmacology 2017 focusing on the advanced technologies to save heart and life.  Working with doctors, scientists, and other subject matter experts, creates awareness that effectively and clearly  explains Vascular interventions, Trans catheter valve technology, Congenital heart  treatments, Coronary interventions, Heart stroke prevention. Conferenceseries LLC organizes a conference series of 3000+ Global Events inclusive of 600+ Conferences, 1200+ Upcoming and Previous Symposiums and 1200+Workshops in USA, Europe & Asia with support from 1000 more scientific societies , 15 million unique visitors per year, 36 million page views per year. Publishes 700+ Open access Journals which contains over 70000 eminent  personalities, reputed scientists as editorial board members with 21 days rapid review process. To know more about the conference series visit: http://www.conferenceseries.com/

Track1: Cardiac Pharmacology

Heart is a muscular organ; it is size of a closed fist. Responsibility of heart is pumping blood through the blood vessels by recurrent, rhythmic contractions. The heart is consisting of cardiac muscle, an involuntary muscle tissue. The term "cardiac" means "related to the heart”. It is a four-chambered, double pump and is located in the thoracic cavity between the lungs. The cardiac muscle is own conduction system. This is in contrast with skeletal muscle, which requires either conscious or reflex nervous stimuli. The heart's rhythmic contractions occur instinctively, although heart rate can be changed by nervous or hormonal influence such as exercise or the perception of danger. 

Related Conferences:

International Conference on Cardiovascular Medicine August 01-02, 2106, UK; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016,  USA; International Conference on Ischemic Heart  Diseases  October 20-21, 2016, USA; 15th Cardiothoracic Meeting, December 08-09, 2106, USA;  Cardiology Issues in Younger Adults  September 15-24, 2016, Italy; Royal Society of Medicine; The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; European Society of Cardiology Congress August 27-31, 2016, Italy.World Heart Federation ( ISFC)European Association for Cardio-thoracic Surgery.

Track2: Types of Cardio Vascular Diseases

CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. CVDs are responsible for over 17.3 million deaths per year and are the leading causes of death in the world .The different types of CVDs are listed below. CVDs due to atherosclerosis: Ischaemic heart disease or coronary artery disease.Cerebrovascular disease, Diseases of the aorta and arteries, including hypertension and peripheral vascular disease. Other CVDs  are Congenital heart disease, Rheumatic heart disease, Cardiomyopathies, Cardiac arrhythmias.

Related Conferences:

International Conference on Cardiovascular Medicine August 01-02, 2106,UK; International Conference on Hypertension & Health Care August 11-12, 2016, Canada ; 10th International Conference on Molecular & Cellular Cardiology August 22-24 Brazil; International Conference on Ischemic Heart  Diseases  October 20-21, 2016 Chicago, USA; 62nd Annual Conference on Association of Cardiovascular And Thoracic Surgeons  February 18-21, 2016, India; European Society of Cardiology Congress August 27-31, 2016, Italy ;  The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; American Heart Association (AHA)British Cardiac Society.

Track3:Cardiovascular Pharmacotherapy and Cardiovascular surgery

Cardiovascular Pharmacotherapy includes Treatment for Cardiovascular disease such as medication, surgery and other procedures. Cardiovascular disease treatments vary by condition. If one has a heart infection, he/she likely is given antibiotics. In general, treatment for heart disease commonly includes: Lifestyle changes like doing exercise regularly, maintaining a proper diet chat, Medications, surgery or Medical procedures. The aims of treatment are to relieve symptoms, lower the risk of blood clots forming, bring down risk factors in an effort to slow, stop, or reverse the build-up of plaque. To Prevent Cardiovascular Disease complications we have to get updated with the treatments of cardiovascular diseases and to do so we will organize Cardiology Conferences every year worldwide. Cardiovascular Surgery on the heart or vessels performed by cardiac surgeons. It is done to treat complications of ischemic heart disease (for example, coronary artery bypass grafting), correct congenital heart disease, or treat valvular heart disease from various causes including endocarditis, rheumatic heart disease and atherosclerosis. It also includes heart transplantation. The development of cardiac surgery and cardiopulmonary bypass techniques has reduced the mortality rates of these surgeries to relatively low ranks. The most common type of heart surgery is Coronary artery bypass grafting (CABG). CABG improves blood flow to the heart. Surgeons use CABG to treat people who have severe coronary heart disease (CHD).

Related Conferences:

13th European Cardiology Congress October 24-26,  2016, Spain;  International Conference on Angiology December 08-09, 2016,  USA; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016, USA;  International Conference on Hypertension  & Treatment  August 11-12,2016 Toronto, Canada; European Society of Cardiology Congress August 27-31, 2016, Italy ; European Association for Cardio-thoracic SurgeryBritish Cardiac Society; The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; International Society for Heart Research (ISHR).

Track4: Risk Factors for Cardiovascular Diseases

There are many risk factors associated with coronary heart disease and stroke. Some risk factors cannot be changed such as family history, ethnicity and age.  Other risk factors that can be treated or changed include tobacco exposure, high blood pressure (hypertension), high cholesterolobesity, physical inactivitydiabetesunhealthy diets, and harmful use of alcohol.In developing countries people are struggling with increasing rates of cardiovascular disease, they still face the scourges of poor nutrition and infectious disease. Cardiovascular disease is the leading cause of death in the developing world. There are different types of risk factors are Behavioural risk factors, Metabolic risk factors, Other risk factors.You will not necessarily develop cardiovascular disease if you have a risk factor.  But the more risk factors you have the greater is the likelihood that you will, unless you take action to modify your risk factors and work to prevent them compromising your heart health.

Relevant Conferences:

15th World Cardiothoracic Meeting December 08-09, 2016, USA; 14th Clinical & Experimental Cardiology conference November 14-16, 2016, USA ; Atherosclerosis Conference July 11-12, 2016, USA; Cardio Vascular Medicine Conference August 1-2, 2016, UK; Angiology Conference December 08-09, 2016, USA; 16th World Cardiology Conference December 08-10, 2016, UAE ;10th Molecular & Cellular Cardiology conference November 28-29, 2016 Brazil ; 13th European Cardiology Congress October 17-19, 2016, Italy ; Hypertension conference August 11-12, 2016, Canada ; European Society of Cardiology Conference August 27-31, 2016 , Italy ; 8th Annual The Heart Beat of Cardiology December 10-12, 2015, USA; European Cardiology Congress August 27-31, 2016,Italy ; American Cardiology association conference April 02-04, 2016, USA; Pre HT 2016 - The fourth International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome, Italy; WCC 2016 - World Congress of Cardiology and Cardiovascular Health, Mexico.International Society for Heart Research (ISHR)International Task Force for Prevention of Coronary Heart DiseaseItalian Society of Cardiology.

Track5: Interventional Cardiology

Interventional cardiology is a branch of cardiology refers specific Cather based techniques to various structural heart diseases, non-surgical procedures for treating cardiovascular disease. Interventional cardiologists use catheters – thin, flexible tube to repair damaged vessels or other heart structures, often avoiding the need for surgery. Many procedures can performed on heart by Catheterization. This most commonly involves the insertion of a sheath into the femoral artery and cannulating the heart under X-ray visualization. Cardiac catheterization is a test which used to evaluate your coronary arteries and heart valve function.

Relevant Conferences:

14th Clinical & Experimental Cardiology conference November 14-16, 2016, USA ;  Cardio Vascular Medicine Conference August 1-2, 2016, UK; Angiology Conference December 08-09, 2016, USA; 16th World Cardiology Conference December 08-10, 2016, UAE ;  10th Molecular & Cellular Cardiology conference November 28-29, 2016, Brazil ; 13th European Cardiology Congress October 17-19, 2016, Italy ; Hypertension conference August 11-12, 2016, Canada ;  European Society of Cardiology Conference August 27-31, 2016, Italy ; 8th Annual The Heart Beat of Cardiology December 10-12, 2016, USA; European Cardiology Congress August 27-31, 2016,Italy ; American Cardiology association conference  2016, USA (PreHT 2016).European Association for Cardio-thoracic SurgeryWorld Health OrganizationWorld Heart Federation ( ISFC).

Track6: Nuclear cardiology and Echocardiography

Echocardiography is a diagnostic test that uses ultrasound waves to create an image of the heart muscle. Ultrasound waves that echo off the heart can show the size, shape, and movement of the heart's valves and chambers as well as the flow of blood through the heart. Echocardiography shows abnormalities as poorly functioning heart valves or damage to the heart tissue from a past heart attack. Echocardiography is used to diagnose certain cardiovascular diseases. In fact, it is one of the most widely used diagnostic tool for heart diseases. It can provide a wealth of helpful information of diseased condition of heart. The conference reaches out the vivid topics in the field of echocardiography. Nuclear cardiology is non-invasive techniques to assess myocardial blood flow, evaluate the pumping function of the heart as well as visualize the size and location of a heart attack. Myocardial perfusion imaging is the most widely used technique of nuclear cardiology. Myocardial perfusion images are combined with exercise to assess the blood flow to the heart muscle. Exercise is most often in the form of walking on the treadmill. A "chemical" of "pharmacological" stress test using the drug dipyridamole, adenosine or dobutamine is performed in patients who are not able to exercise maximally, providing similar information about the heart's blood flow.

Relevant Conferences:

13th European Cardiology Congress October 24-26,  2016, Spain;  International Conference on Angiology December 08-09, 2016,  USA; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016, USA;  International Conference on Hypertension  & Treatment  August 11-12,2016 Toronto, Canada; European Society of Cardiology Congress August 27-31, 2016, Italy ;  The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; World Heart Federation (ISFC)International Society for Heart Research (ISHR)British Cardiac Society.

Track7: Cerebrovascular heart Diseases

Cerebral vascular disease is caused by atherosclerosis, that is the narrowing and blockage of the blood vessels that flow to the brain. If the flow of blood is cut off this can lead to strokes and transient ischemic attacks.Brain Stroke A stroke occurs when the blood supply to the brain is interrupted. It happens either when a blood vessel in the brain or neck is blocked or bursts or brain is deprived of oxygen and parts of brain may be permanently damaged. The consequences of a stroke can include problems with speech or vision, weakness or paralysis.Transient ischemic attacks Just as stroke occurs when the flow of blood is blocked, TIAs happen when there is a brief blockage. The temporary loss of blood to the brain causes a brief, sudden change in brain function.  This may manifest as temporary numbness or weakness on one side of the body, loss of balance, confusion, and blindness in one or both eyes, double vision, difficulty speaking, or a severe. But these will disappear quickly and permanent damage is unlikely.Dementia The additive effects of multiple small strokes, together with microangiopathy affecting the small blood vessels to the brain, lead to an increased likelihood of dementia in people with diabetes.

Relevant Conferences:

International Conference on Cardiovascular Medicine August 01-02, 2106, UK; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016,  USA; International Conference on Ischemic Heart  Diseases  October 20-21, 2016, USA; 15th Cardiothoracic Meeting, December 08-09, 2106, USA;  Cardiology Issues in Younger Adults  September 15-24, 2016, Italy; Royal Society of Medicine; The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; European Society of Cardiology Congress August 27-31, 2016, Italy.World Heart Federation ( ISFC)European Association for Cardio-thoracic Surgery.

Track 8:  Complications of diseases associated Cardiovascular Diseases

Diabetes can lead to cardiovascular damage in a number of ways. The processes do not develop independently, as each may accelerate or worsen the others. Thus, as diabetes progresses, the heart and blood vessels are exposed to multiple attacks. The cardiovascular complications of diabetes are therefore a major cause of illness, death and healthcare costs. Cardiovascular death rates are either high or appear to be climbing in countries where diabetes is prevalent.People with type 2 diabetes also have high rates of high blood pressure, lipid problems, and obesity, which contribute to their high rates of CVD. Smoking doubles the risk of CVD in people with diabetesHypertensionIt is a risk factor for coronary heart disease and the single most important risk factor for   stroke. There are at least 970 million people worldwide who have hypertension. It causes about 50% of ischaemic strokes and increases the risk of haemorrhagic stroke. Hypertension stresses human body’s blood vessels, causing them to clog or weaken.  Hypertension can lead to atherosclerosis and narrowing of the blood vessels making them more likely to block from blood clots or bits of fatty material breaking off from the lining of the blood vessel wall. Chronic kidney disease (CKD) is a worldwide public health problem. Kidney failure requiring treatment with dialysis or transplantation is the most visible outcome of CKD. However, cardiovascular disease (CVD) is also frequently associated with CKD, which is important because individuals with CKD are more likely to die of CVD than to develop kidney failure, CVD in CKD is treatable and potentially preventable, and CKD appears to be a risk factor for CVD. CKD exposes the heart to three major mechanisms that  Facilitate the development of cardiomyopathy, LV failure: pressure overload, volume overload.The plasma lipoproteins are the primary means of transport of cholesterol among tissues. In particular, the apo B-containing lipoproteins (VLDL, IDL and LDL) are important for the delivery of cholesterol from the liver to peripheral tissues, while HDL appear to mediate the reverse process of movement of cholesterol from tissues back to the liver. Both of these transport processes are necessary for efficient whole body cholesterol homeostasis, because the liver is the major site of both the production and excretion of cholesterol. However, deviations from a proper balance of transport of cholesterol, either increases in LDL levels or decreases in HDL cholesterol flux, may result in accumulation of cholesterol in extra hepatic tissues. Increased risk of atherosclerosis and CHD may be associated with elevation in the number of LDL particles, increase or decrease in LDL particle size, or changes in the composition of plasma LDL.

Relevant Conferences:

Ischemic Heart Diseases Conference October 20-21, 2016, USA; Hypertension & Health Care Conference August 11-12, 2016, Canada; 11th Cardiac Conference September 12-13, 2016, USA; 13th European Cardiology Congress  October 17-19, 2016, Italy; American Cardiology Congress 2016; ACC Annual Meeting 2016; American Cardiology Congress 2016;  European Cardiology Congress August 27-31, 2016 Rome,  Italy; 21st World Congress on Heart Disease,  July 30-August 1, 2016, USA; Cardiac Society of Australia and New ZealandEuropean Association for Cardio-thoracic SurgeryInternational Academy of Cardiology (IAC).

Track 09: Heart diseases in different Rationale 

Although CVD has sometimes been considered a disease that predominantly affects men, it is the leading cause of death among both men and women globally. There are number of notable gender differences in CVD incidence, mortality, risk-factor profiles, outcomes, and clinical presentation. These differences remain consistent across populations and regions and are thus important to consider when developing CVD prevention and treatment programs.

Relevant Conferences:

International Conference on Cardiovascular Medicine August 01-02, 2106, UK; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016,  USA; International Conference on Ischemic Heart  Diseases  October 20-21, 2016, USA; 15th Cardiothoracic Meeting, December 08-09, 2106, USA;  Cardiology Issues in Younger Adults  September 15-24, 2016, Italy; Royal Society of Medicine; The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; European Society of Cardiology Congress August 27-31, 2016, Italy.World Heart Federation ( ISFC)European Association for Cardio-thoracic Surgery.

Track 10: Cardiologists and Angiologists

Cardiologists are physicians or doctors who specialize in treating diseases or conditions of the heart and diagnosing the whole blood vessels i.e. cardiovascular system. One must visit a cardiologist so they can learn about their risk factors for Cardiac or heart disease and find out what measures should be taken for better heart health. When one is dealing with heart disease, it is important that they must find the right match between them and their specialist and for that, basic knowledge on cardiology is much needed. To make it possible Cardiology Conferences are organised to spread the awareness to control this heart related sufferings and problems.

Cardiovascular Medicine Conference August 01-02, 2016, UK; 11th International Cardiac conference September 14-15, 2016,USA; 15th World Cardiothoracic Meeting December 08-09, 2016, USA; American Cardiology Congress2016; ACC Annual Meeting 2016; American Cardiology Congress 2016;  European Cardiology Congress August 27 - 31 ,2016 Italy;  International conference and Expo on Cardiology and Cardiac surgery April 04-06, 2016, Dubai, UAE; 21st World Congress on Heart Disease,  July 30-August 1, 2016, USA; Royal Society of MedicineThe American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)Austrian Society of Cardiology.

 

Track`11: Emerging epidemic of cardiovascular disease in developing countries

As the 20th century era to a close, Cardiovascular disease (CVD) becomes a ubiquitous cause of morbidity and a principal contributor to mortality in most countries. The major risk factors through population-based studies and effective control approaches combining community education and targeted management of high risk individuals added to the fall in CVD mortality rates that observed in almost all industrialized & modernized countries.

Relevant Conferences:

Cardio Vascular Medicine Conference August 1-2, 2016, UK; Angiology Conference December 08-09, 2016, USA; 16th World Cardiology Conference December 08-10, 2016, UAE ; Echo Cardiography Conference July 18-19, 2016, Germany; 10th Molecular & Cellular Cardiology conference November 28-29, 2016 Brazil ; 13th European Cardiology Congress October 17-19, 2016, Italy ; Hypertension conference August 11-12, 2016, Canada ; European Society of Cardiology Conference August 27-31, 2016 , Italy ; 8th Annual The Heart Beat of Cardiology December 10-12, 2015, USA; European Cardiology Congress August 27-31, 2016,Italy ; Pre HT 2016 - The fourth International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome, Italy; WCC 2016 - World Congress of Cardiology and Cardiovascular Health, Mexico; Society for Cardiac Angiography & InterventionsWorld Heart Federation (ISFC)American Heart Association (AHA).

Track12:  Cardio toxicity

Cardio toxicity is the occurrence of heart electrophysiology dysfunction or muscle damage. The heart becomes weaker and is not as efficient in pumping and therefore circulating blood. Cardio toxicity may be caused by chemotherapy. Treatment complications are anorexia nervosa, adverse effects of heavy metals intake, or an incorrectly administered drug such as bupivacaine. One of the ways to detect cardio toxicity at early stages when there is a sub conical dysfunction is by measuring changes in regional function of the heart using strain.

Related conferences: 

Ischemic Heart Diseases Conference October 20-21, 2016, USA; Hypertension & Health Care Conference August 11-12, 2016, Canada; 11th Cardiac Conference September 12-13, 2016, USA; 13th European Cardiology Congress  October 17-19, 2016, Italy; American Cardiology Congress 2016; ACC Annual Meeting 2016; American Cardiology Congress 2016;  European Cardiology Congress August 27-31, 2016 Rome,  Italy; 21st World Congress on Heart Disease,  July 30-August 1, 2016, USA; Italian Society of CardiologyEuropean Association for Cardio-thoracic SurgeryCardiac Society of Australia and New Zealand

Track 13: Cardiovascular regeneration and tissue engineering

Stem cell therapy and tissue engineering represent a forefront of current research in the treatment of heart disease. With these technologies, advancements are being made into therapies for acute ischemic myocardial injury and chronic, otherwise non reversible, myocardial failure. The current clinical management of cardiac ischemia deals with re-establishing perfusion to the heart but not dealing with the irreversible damage caused by the occlusion or stenosis of the supplying vessels. The applications of these new technologies are not yet fully established as part of the management of cardiac diseases but will become so in the near future. The discussion presented here reviews some of the pioneering works at this new frontier. Key results of allogeneic and autologous stem cell trials are presented, including the use of embryonic, bone marrow-derived, adipose-derived, and resident cardiac stem cells.

Related conferences: 

Ischemic Heart Diseases Conference October 20-21, 2016, USA; Hypertension & Health Care Conference August 11-12, 2016, Canada; 11th Cardiac Conference September 12-13, 2016, USA; 13th European Cardiology Congress  October 17-19, 2016, Italy; American Cardiology Congress 2016; ACC Annual Meeting 2016; American Cardiology Congress 2016;  European Cardiology Congress August 27-31, 2016 Rome,  Italy; 21st World Congress on Heart Disease,  July 30-August 1, 2016, USA; Italian Society of CardiologyEuropean Association for Cardio-thoracic SurgeryCardiac Society of Australia and New Zealand

Track14: Case Reports on Cardiology

Our all Cardiology conferences has Case Studies act as informative examples to people who might also faces similar problems. Generally, Case Studies in Cardiovascular disease, should detail a particular medical case, reporting the background of the patient. They should discuss investigations undertaken in order to determine a diagnosis or differentiate between possible diagnoses, and should indicate the type of treatment the patient underwent as a result. In one piece we can conclude that Case Studies is an useful and informative part of every doctor or physician's medical education, which actually encourage us to include this session track on our

Related Conferences

International Conference on Cardiovascular Medicine August 01-02, 2106, UK; 14th International Conference on Clinical and Experimental Cardiology November 07-09 , 2016,  USA; International Conference on Ischemic Heart  Diseases  October 20-21, 2016, USA; 15th Cardiothoracic Meeting, December 08-09, 2106, USA;  Cardiology Issues in Younger Adults  September 15-24, 2016, Italy;  The Cardiac Society of Australia and New Zealand ASM August 4-7, 2016; European Society of Cardiology Congress August 27-31, 2016, Italy; The American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)Austrian Society of CardiologyWorld Heart Federation (ISFC).

Track15: Cardiovascular Nursing

Cardiovascular nursing is a specialty that works with patients who suffer from numerous conditions of the cardiovascular system. Cardiovascular nurses facilitate treat conditions like unstable angina, myocardial infarction, cardiomyopathycoronary artery disease, cardiac dysrhythmia and congestive heart failure under the direction of a heart specialist (cardiologist). Cardiovascular nurses perform postoperative care on a stress test evaluations, cardiac monitoring, surgical unit, health assessments and vascular monitoring. Cardiovascular nurses must have Advanced Cardiac Life Support and Basic Life Support certification. Cardiovascular nurses must possess specialized skills including defibrillation, electrocardiogram monitoring and medication administration by continuous intravenous drip. Cardiovascular nurses care for people with Cardiovascular Disease and interact with their patients families. They may monitor and treat acutely ill patients, or they may focus on cardiovascular rehabilitation helping patients make lifestyle changes to prevent the worsening of their disease.

Relevant Conferences:

 Cardio Vascular Medicine Conference August 1-2, 2016, UK; Angiology Conference December 08-09, 2016, USA; 16th World Cardiology Conference December 08-10, 2016, UAE ; Echo Cardiography Conference July 18-19, 2016, Germany; 10th Molecular & Cellular Cardiology conference November 28-29, 2016 Brazil ; 13th European Cardiology Congress October 17-19, 2016, Italy ; Hypertension conference August 11-12, 2016, Canada ;  European Society of Cardiology Conference August 27-31, 2016 , Italy ; 8th Annual The Heart Beat of Cardiology December 10-12, 2015, USA; European Cardiology Congress August 27-31, 2016,Italy ; Pre HT 2016 - The fourth International Conference on Prehypertension, Hypertension and Cardio Metabolic Syndrome, Italy; WCC 2016 - World Congress of Cardiology and Cardiovascular Health, Mexico; World Heart Federation( ISFC)Royal Society of MedicineInternational Society for Heart Research (ISHR).

Track16: Clinical trials in Cardiology

Clinical trials in cardiology research investigations are being conducted in which people of cardiac failures or disorders volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various cardiovascular diseases or medical conditions. Some investigations look at how people respond to a new intervention and the side effects which might occur. This helps to determine if a new intervention works, if it is safe, and if it is better than the interventions that are already available. Clinical trials might also compare existing interventions, test new ways to use or combine existing interventions or observe how people respond to other factors that might affect their health such as dietary changes.Angiologists are physicians or doctors who specialize in treating diseases or conditions of the circulatory system, lymphatic system (arteries, veins and lymphatic vases)

Related conferences:

Cardiovascular Medicine Conference August 01-02, 2016, UK; 11th International Cardiac conference September 14-15, 2016,USA; 15th World Cardiothoracic Meeting December 08-09, 2016, USA; American Cardiology Congress2016; ACC Annual Meeting 2016; American Cardiology Congress 2016;  European Cardiology Congress August 27 - 31 ,2016 Italy;  International conference and Expo on Cardiology and Cardiac surgery April 04-06, 2016, Dubai, UAE; 21st World Congress on Heart Disease,  July 30-August 1, 2016, USA; Royal Society of MedicineThe American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)Austrian Society of Cardiology.

Track17: Cardiovascular Drugs Market Analysis

We will examine recent variability and statistics regarding survival rates from cardiac arrest and industries related to Cardiovascular Medicine which will focus on challenging areas of research and it will assist us to steps ahead to improve the quality of care for cardiac problems like heart arrest etc. To meet the increasing demand for cardiovascular services and to ensure excellence in cardiac care delivery, on a series of upgrades and renovations that will enhance its ability to provide not only prompt also expert medical treatment, and even the best patient experience possible. This study will focus on the following topics: 3-D “Bioprinter, Information Technology, Thrombolytic [clot-busting] drug, Mobile Cardiovascular medicine apps, Social Media and Cardiovascular Medicine.

Relevant Conferences:

 14th Clinical & Experimental Cardiology conference November 14-16, 2016, USA ;  Cardio Vascular Medicine Conference August 1-2, 2016, UK; Angiology Conference December 08-09, 2016, USA; 16th World Cardiology Conference December 08-10, 2016, UAE ; 10th Molecular & Cellular Cardiology conference November 28-29, 2016, Brazil ; 13th European Cardiology Congress October 17-19, 2016, Italy ; Hypertension conference August 11-12, 2016, Canada ;  European Society of Cardiology Conference August 27-31, 2016, Italy ; 8th Annual The Heart Beat of Cardiology December 10-12, 2016, USA; European Cardiology Congress August 27-31, 2016,Italy ;American Cardiology association conference  2016, USA (PreHT 2016)German Cardiac Society (GCS)European Association for Cardio-thoracic SurgeryBritish Cardiac SocietyAmerican Heart Association (AHA).

Conference Series LLC is a renowned organization that organizes highly notable pharmaceutical conferences throughout the globe. Currently we are bringing forth Global Experts Meeting on Cardiovascular Pharmacology and Cardiac Medications” (Cardiac Pharmacology 2017) scheduled to be held during April 13-14, 2017 at Dubai, UAE. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Cardiovascular System and Medication.

Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2017 Highlights:

  • 300+ Participation (70 Industry: 30 Academia)
  • 5+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings

CardiacPharmacology 2017 is comprised of 17 tracks designed to offer comprehensive sessions that addresses current issues in Cardiovascular diseases. Conference Series LLC  organizes 300+conferences, 500+workshops such as electrocardiography workshops, CVDs diagnosis workshops, cardio myopathy workshops cardiology exhibitions and 200+symposiums on ClinicalMedicinePharma and Science & Technology. 

This conference will provide a comprehensive update on all medical, surgical, interventional, and electrophysiological topics in Cardiovascular diseases and Medication. Experts with national and international reputations in various cardio sub-specialties will address the latest guidelines, practice patterns and solutions in cardiovascular medicine. Additionally, attendees will learn about recent trials being practiced that are likely to influence future practices. Interactive sessions will include discussion of current controversies in clinical practice. The areas of Cardiac Pharmacology 2017 will be covered include: heart disease, imaging, heart failure, arrhythmias, prevention and general cardiology, cardiovascular surgery, Clinical research In CVDs and interventional cardiology.

Cardiac Pharmacology events are every year across USA, Europe, Asia, Middle East, Australia and UK that support cardiology medical conferences from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. 

 According to the American Heart Association, there are approximately 6000 hospitals in the US with only 23,000 cardiologists to cover 6000 hospitals, there’s no doubt that there is a current shortage of cardiologists in the US.

With continuing advances in all areas of cardiovascular medicine, there is a need to update general and sub-specialist cardiologists on the state of the art, rapidly-evolving developments in the field. Upon completion of this course, participants should have an increased understanding of changes in practice standards and recent clinical advancements in cardiovascular medicine. An additional objective of this meeting is to provide practical knowledge and tips to improve the practice of CVDs and Medication. This conference will benefit all levels of cardiology practitioners, including doctors, professors, nurses, PhD scholars and technicians.

Cardiac Pharmacology2017 invites all interested participants to join us for this esteemed event at the exquisite destinationDubai. For more information: conference series.com

Why to attend?

6th Global Experts Meeting on Cardiovascular Pharmacology and Cardiac Medications is among the World's leading Scientific Conference. The three day event on Cardiovascular Diseases and Medication  will host 60+ Scientific and technical sessions and sub-sessions on cutting edge research and latest research innovations in the field of cardiology and cardiac surgeries across the globe. This year annual Cardiac conference will comprises of 13 major sessions designed to offer comprehensive sessions that address current issues in various field of CVDs. The attendees can find-

Exclusive Sessions and Panel discussions on latest innovations in Cardiac Surgeries and Heart Failure-

Lectures by active practitioners
Keynote forums by Prominent Professors, Doctors
Open Innovation Challenges
Poster presentations by Young Researchers
Global Networking sessions with 50+ Countries
Novel techniques to benefit your research
Best platform for Global business and Networking opportunities
Meet the editors of referred journals, Society and Association members across the Globe
Excellent platform to showcase the latest products and formulations in Cardiac field

Target Audience:

Cardiologists
Cardiac Surgeons
University Professors
Various Societies and their members
Institutes-Medical Schools
Academicians: University Faculties, Research Scholars, and Scientists involved

 

               Title: 6th Global Experts Meeting on Cardiovascular Pharmacology and Cardiac Medications

                                                 Date & Venue: April 13-14, 2017 Dubai, UAE

                                               Theme: Drugs Affecting the Rhythm of the Heart

Summary of Cardiac Pharmacology 2017 Conference:-

Cardiac Pharmacology 2017 is a platform for advanced technologies and provides a complete knowledge of a scientific discipline that described the future and present trends in Cardiac research field and comprehensive update on all medical, surgical, interventional, and electrophysiological topics in cardiology.

Cardiovascular disease (CVD) is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such as ischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others. These disorders are mainly reported due to obesity, high cholesterol, smoking, excessive alcohol, and poor lifestyle. According to the World Health Organization (WHO), CVD is responsible for approximately 15 million deaths each year across the globe. The same source also states that it is a major cause of death in adults and accounts for 50% of total deaths worldwide.

Cardiovascular diseases can be prevented or treated using various medications. Major drugs prescribed for the treatment of cardiovascular diseases includes heparin, Coumadin (warfarin), Sectral (acebutolol), Zebeta (bisoprolol), Lopressor, Toprol XL (metoprolol), Norvasc, Lotrel (amlodipine), Vascor (bepridil) andSular (nisoldipine).

The market for cardiovascular drugs can be categorized drug class on the basis of mechanism of action: beta blockers, beta agonists, alpha blockers, alpha agonists, sodium channel blockers, calcium channel blockers, vasodilators, renin inhibitors, angiotensin receptor blockers, diuretics, and thrombolytics. Furthermore, the CVD market can also be subdivided based on various indications such as stroke, hypertension, dyslipidemia and others. In terms of geography, the market can be analyzed by major geographies: North America, Europe, Asia-Pacific, Latin America and Rest of the World.

•           Antihypertensive drug class holds the largest share of the global CVD market in terms of revenue

•          Geographically, North America accounted for the highest market share in 2013 due to high awareness about the heart diseases According to the Centers for Disease Control and Prevention (CDC), every year about 610,000 people in America die of heart diseases. Likewise, annually 735,000 Americans are victims of heart attacks. Thus, increasing incidence of heart attacks in North America would surge the demand for cardiovascular drugs.

OBJECTIVES

This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease sub segments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

  • The cardiovascular therapeutic market is the largest of any drug sector.
  • Mrket growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as P2Y12 inhibitors and Factor Xa inhibitors. In contrast to technical innovation, patent expiry is producing a severe headwind as evidenced by Lipitor and Plavix which are expected to drop $19 billion in one-year sales in 2015 from 2010.
  • Introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period.

SCOPE:

  • Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected.
  • The report includes analysis of leading and emerging competitors in the current worldwide cardiovascular market.
  • Market figures are based on revenues at the manufacturers’ level and are projected at 2010-dollar value.
  • The study is arranged to offer an overview of the cardiovascular market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease sub segment.  
  • Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

Some companies are operating key role in the cardiovascular disease drug market are

  • AstraZeneca plc,
  • Pfizer, Inc., Sanofi S.A.,
  •  Merck & Co., Daiichi Sankyo Company Limited,
  •  Novartis AG, Bayer AG,
  • Takeda Pharmaceutical Company Limited,
  •  Boehringer Ingelheim GmbH,
  •  Astellas Pharma Inc.,
  • Johnson & Johnson,
  •  United Therapeutics Corporation,
  •  Actelion Pharmaceuticals Ltd.
  • Roche Holding AG.

Why Dubai, UAE:

Cardiovascular disease (CVD) continues to be the leading cause of death and disability in the world today: over 17.3 million people die from cardiovascular disease every year.

Any disease of the heart, vascular disease of the brain, or disease of the blood vessel constitutes as a cardiovascular disease. The most prevalent cardiovascular diseases include coronary heart disease (e.g. heart attack) and cerebrovascular disease (e.g. stroke). Controlling key risk factors such as diet, physical activity, tobacco use, and blood pressure may reduce your risk for CVD.

The comfort of Dubai’s luxury lifestyle can come at a price to your health. Poor diet and a lack of exercise mean diabetes and obesity rates are alarmingly high compared to global averages, while another looming threat is heart disease. In the UAE, 41 percent of under 30s suffer from high blood pressure (a risk factor for heart attack and stroke), compared to a global average of 25-30 percent, and it is anticipated the figure could rise to as high as 60 percent by 2025.

In 2013, 850 heart-attack patients were admitted to Rashid Hospital in Dubai. A troubling statistic in itself, the even more sobering news was the average age of the first-time heart attack patients. Whereas the global average is 65 years, the average age of the Rashid Hospital patients was 45 years. Additionally, of those 850 patients, “40 percent were diabetic, 40 percent were hypertensive and 25 percent had high levels of cholesterol.”

In UAE, Diabetes is a major risk factor for heart attacks, because more than 20 per cent of UAE’s population is diabetic. Similarly, the percentage of people with obesity, hypertension, and high cholesterol is also very high in UAE.

 Tobacco consumption is another significant cause for cardiovascular diseases in UAE, evidenced by the fact that more than 50% of the heart attack patients admitted in Rashid Hospital in 2013 were smokers.

The high risk of heart disease in the region can also be attributed to a poor diet and the high consumption of fat and carbohydrates.

 

Some of the other factors causing CVD are

  • Being physically inactive
  •  Being overweight or obese
  • Family history of heart disease
  •  Ethnic background
  •   Sex – men are more likely to develop CVD at an earlier age than women.
  • Age – the older you are, the more likely you are to develop CVD.

Conference highlights:

  •  Cardiac Pharmacology
  •  Types of Cardiovascular Diseases
  • Cardiovascular Pharmacotherapy and Cardiovascular surgery
  •  Risk Factors for Cardiovascular Diseases
  • Interventional Cardiology
  •  Nuclear Cardiology and Echocardiography
  •  Cerebrovascular Heart Diseases
  •  Diseases associated with Cardiovascular Diseases
  •  Heart Diseases in Different Rationale
  • Cardiologists and Angiologists
  •  Emerging epidemic of cardiovascular disease in developing countries
  • Cardiotoxicity
  • Cardiovascular and biological tissue regeneration and tissue engineering
  • Case Reports on Cardiology
  •   Cardiovascular Nursing
  •  Clinical trials in Cardiology
  •   Cardiovascular Drugs Market Analysis

Why to attend?

World cardiology congress is a unique forum to bring together worldwide distinguished academics in the field of cardiology, cardiovascular researchers, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies.

Top ranked hospitals in Dubai, UAE:

·         American Hospital Dubai

·         Jebel Ali Hospital (Lifeline Hospital)

·         Emirates Hospital

·         Dubai Hospital (Govt)

·         Rashid Hospital (Govt)

·         Medcare Hospital

·         Aster Hospital

·         Canadian Specialist Hospital

·         Beloul Speciality Hospital

·         Welcare Hospital

·         Zuleka Hospital

·         Latifa Hospital (Al Wasl Hospital) (Govt)

·         British Medical Consulting Centre (BMCC)

Associations & Societies for cardiology in UAE:

·         Emirates Cardiac Society

Associations & Societies for cardiology worldwide:

·         American Association of Cardiovascular and Pulmonary Rehabilitation

·         American Society for Preventive Cardiology

·         Australian Cardiovascular Health and Rehabilitation Association

·         British Association for Cardiovascular Prevention and Rehabilitation

·         Canadian Association of  Cardiovascular Prevention and  Rehabilitation

·         Iranian Heart Foundation

·         Irish Association of Cardiac Rehabilitation

·         National Society for the Prevention of Heart Disease and Rehabilitation (India)

·         Nigerian Heart Foundation

·         The Saudi Group for CardioVascular Prevention and Rehabilitation

·         Singapore Heart Foundation

·         World Hypertension League

·         Russian National Medical Society for Preventive Cardiology

·         Heart & Stroke Foundation of Barbados

·         Heart Friends Around the World

·         South African Sports Medicine Association

 

Universities in Dubai :

·         Zayed University

·         Biotechnology University College Dubai (BUC)

·         The Higher Colleges of Technology (HCT)

·         American University in Dubai (AUD)

·         University of Wollongong in Dubai (UOWD)

·         British University in Dubai (BUiD)

·         American University in the Emirates (AUE)

 

Universities in UAE:

·         Higher Colleges of Technology

·         United Arab Emirates University

·         Masdar Institute of Science and Technology

·         American University of Sharjah

·         University of Sharjah

·         Zayed University

·         American University in Dubai

·         Khalifa University of Science, Technology and Research

·         University of Wollongong in Dubai

·         Ajman University of Science and Technology

·         Abu Dhabi University

·         The Petroleum Institute

·         American University of Ras Al Khaimah

·         Al Ain University of Science and Technology

·         Rochester Institute of Technology, Dubai

·         University of Dubai

·         Manipal University, Dubai

·         Ittihad University

·         Canadian University of Dubai

·         The British University in Dubai

·         American University in the Emirates

·         Amity University Dubai

·         Al Ghurair University

 

Universities Associated with Cardiology Research:

Europe:

  • University Maastricht/Academic Hospital Maastricht
  • Medical University of Graz
  • University of Debrecen Medical School
  • University of Nicosia Medical School
  • Imperial College London
  • Johns Hopkins University
  • Bukovinian State Medical University
  • Heidelberg University
  •  Hamburg university
  • University of Lodz

Universities Associated with Cardiology Research: World Wide:

  • Vanderbilt University
  • University of Washington
  • University of Michigan
  •  Harvard University
  • University of Texas Southwestern medical center
  • University of Alabama-Birmingham
  •  Emory University
  • Yale University
  • Northwestern University
  • Vanderbilt University
  •  University of Rochester

REPORT HIGHLIGHTS

The global cardiovascular therapeutic drug market was worth $140.7 billion in 2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7% to $144.5 billion in 2010.  This market will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to reach $139.8 billion in 2015, a CAGR of -0.7%.

The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies.  The market is expected to grow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7 billion, a compound annual growth rate (CAGR) of -3.9%.

Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009.  Large therapeutic drugs including Lipitor and Crestor comprise a high concentration of this segment.  Driven by patent expirations for Lipitor, and other drugs within this segment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%.

The WHO estimates that 15 million people suffer from stroke each year worldwide, 5.7 million of whom die.This makes stroke the second-leading cause of death globally, responsible for 9.7% of deaths. These WHO estimates also indicate that the share of deaths due to stroke may rise to 12.1% globally in 2030. A stroke occurs when brain cells die owing to a lack of blood supply, resulting from thrombosis, embolism, or hemorrhage. This may lead to permanent neurological damage. Some studies have concluded that transient ischemic attack (TIA), caused by extracranial emboli or atherosclerosis of intracranial small arteries, may be considered a warning signal for strokes.

Estimated prevalence of stroke across the 7MM, 2016

Country

Prevalence (000s)

Prevalence (%)

Share (%)

France

80

0.1

5

Germany

127

0.2

8

Italy

112

0.2

7

Spain

90

0.2

6

UK

103

0.2

7

EU5

512

 

34

US

759

 

50

Japan

247

 

16

Total

1518

 

100

Source: American Heart Association, National Health Statistics, CDC, WHO BUSINESS INSIGHTS

Global cardiovascular market, 2015

 

Geographical region

 

Market size 2010 ($bn)

 

Market share 2010 (%)

 

CAGR 2010–16 (%)

 

US

68

40

 

-8.5

EU5

30.6

 

18

-0.1

Japan

28.9

 

17

0.6

ROW

42.5

25

 

1.9

Total

170

100

 

1.6

Source: company reported sales                                                                                      BUSINESS INSIGHTS

 Market Value on Cardiology Research

The Cardiac Monitoring devices are categorized into electrocardiogram devices, event monitors, implantable loop recorders, and cardiac output monitoring devices. Cardiac monitoring and cardiac rhythmic management devices will be the fastest growing product in market, $21,137.7 Million in 2015is reached to $26,646.5 Million by 2020. The electrocardiogram devices will also be the fastest-growing product during the forecast period. Increasing incidences of cardiovascular diseases and launch of technologically advanced products are the major factors driving the market.

The global interventional cardiology and peripheral vascular devices market is 8.73 Billion with drug-eluting stents comprising the largest segment of the market, followed by coronary vascular closure devices, PTCA and cutting balloon catheters, bare-metal stents, intravascular ultrasound (IVUS) catheters, coronary introducer sheaths, interventional coronary guide wires, coronary embolic protection devices, interventional coronary catheters and balloon-inflation syringes.  Congenital heart defects are the most common birth defects affecting approximately 1% of the births every year. The treatment of cardiovascular disorders has changed dramatically due to the introduction of new drug therapies and devices such as guide wires and stents allowing the patient to live better quality and longer lives.

The fastest growing areas of the cardiac surgery market will be that of transcatheter heart valve devices. These devices are used for repairing and replacing heart valves without the need for open surgery. Cardiovascular industry growth continues to increase with the presence of multiple technologies such as advanced material and software which is featured in most of the devices. International companies tends to innovate, develop new products and to enhance the existing features in cardiac devices.Global Market Analysis:

The global market for cardiovascular diagnostics and therapy increased from $111 billion in 2006 to an estimated $119.8 billion in 2007. It should reach $192.4 billion through 2012, a compound annual growth rate (CAGR) of 9.9%. The cardiovascular diagnostics market represents one of the largest sectors in the diagnostics industry chiefly due to the high prevalence rate of and mortality from cardiovascular disease. Of the cardiovascular diagnostics, devices and drugs markets, the drugs market is the largest, worth an estimated $82.4 billion in 2007 and expected to reach $121.6 billion in 2012.

Growth of market in Cardiology Surgery Research:

In 2011 the world market for coronary stent devices reached $7.1 billion. And it is expected that total market value will reach $10.6 billion in 2016, a projected compound annual growth rate of between 2011 and 2016 is 8.3%. The world market for cardiac medical devices is expected to reach about $67.5 billion in 2019. The global market for cardiac equipment growth had risen from $49.4 billion in 2013 to $52 billion in 2014. The market for heart-lung and pump machines and grew from $2.6 billion in 2012 to $3.4 billion in 2014. This market is expected to experience a annual growth rate of 14.7% in the next few years.

Ethnopharmacology 2016

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, Associations and Exhibitors for making Ethnopharmacology 2016 Conference the best ever!

The 2nd International Conference and Exhibition on Pharmacology and Ethnopharmacology, hosted by the Conferenceseries LLC was held during May 02-04, 2016 at Chicago, USA based on the theme Pharmacological Frontiers for Natural Products Drug Discovery and Development ". Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Pharmacology and Ethnopharmacology, who made this event a grand success.

Conferenceseries LLC expresses its gratitude to the conference Moderator, namely Dr. Francois Simard for taking up the responsibility to coordinate during the sessions. We are indebted to your support.

Similarly we also extend our appreciation towards our Poster judge namely, Dr. Ian James Martins.

A very special Thanks to our Exhibitors and Sponsors to have bestowed and their faith and invested in us to make this event a fruitful one. We hope you continue your support in our future endeavours.  

The conference was initiated with the Honourable presence of the Keynote forum. The list includes:

  • David H KinderOhio Northern University College of Pharmacy, USA
  • Ian James Martins, Edith Cowan University, Australia
  • Mohammed Hmamouchi, President of the Arab Federation Aromatic and Medicinal Plants, Morocco
  • Yibin Feng, The University of Hong Kong, Hong Kong

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Pharmacology
  • Pharmacokinetics and Pharmacodynamics
  • Latest Trends in Ethnopharmacology
  • Phytochemical Studies of Plants and Plant Extracts
  • Ecological Characteristics of Ethnobotanical Sources
  • Phytochemistry and Phytopharmaceuticals
  • Natural Products in Clinical Pharmacology
  • Traditional Herbals in Treatment of Cancer
  • Ethnopharmacology of Medicinal Plants
  • Nutraceuticals
  • Emerging Technology in Natural Product Drug Development
  • Neuropharmacology
  • Cardiovascular Pharmacology and Diabetes
  • Ethnopharmacology of Alkaloids
  • Intercultural of Ethnopharmacology
  • Entrepreneurs Investment Meet

Conference Series LLC offers its heartfelt appreciation to organizations such as Business with IndiaRE news IndiaMNTThe Pharma Times.in Market-Width.com, and other eminent personalities who supported the conference by promoting in various modes online and offline which helped the conference reach every nook and corner of the globe. Conference Series LLC also took privilege to felicitate the Keynote Speakers, Organizing Committee Members, Chairs and Exhibitors who supported this event.

With the grand success of Ethnopharmacology 2016Conference Series LLC is proud to announce the "6th Global Experts Meeting on Cardiovascular Pharmacology and Cardiac Medications" to be held during April 13-14, 2017 at Dubai, UAE.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date April 13-14, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Conferenceseries Destinations